Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Sclerosis Relapse Clear all

Conditions: Multiple Sclerosis
Interventions: Avonex and Topamax; Drug
Lead sponsor: Multiple Sclerosis Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Relapsing Multiple Sclerosis
Interventions: Rebif New Formulation Non Titrated, Rebif New Formulation Titrated; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: 19 nor vitamin d; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Relapsing Remitting Multiple Sclerosis, Sleep Initiation and Maintenance Disorders, Fatigue
Interventions: eszopiclone, placebo; Drug · Other
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 64 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Multiple Sclerosis
Interventions: Blood draw for future biomarker analysis; Other
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: RG2077 (CTLA4-IgG4m); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions: Tolebrutinib, Placebo, Teriflunomide; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 52
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 47 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Remibrutinib, Teriflunomide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,007 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 50
States / cities: Phoenix, Arizona • Hanford, California • Los Angeles, California + 42 more

Conditions: Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Interventions: Ublituximab; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Ublituximab; Biological
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 8
States / cities: Pasadena, California • Aurora, Colorado • Lexington, Kentucky + 5 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Spinal Manipulation, Sham Spinal Manipulation; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Zeposia; Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 64 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: dimethyl fumarate, Interferon β-1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts • Charlottesville, Virginia

Conditions: Multiple Sclerosis
Interventions: rituximab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 31
States / cities: Phoenix, Arizona • Loma Linda, California • Modesto, California + 28 more

Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Interventions: Ocrelizumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Relapsing Multiple Sclerosis
Interventions: Laquinimod; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: Not listed
Enrollment: 1,047 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 22
States / cities: Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more

Conditions: Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis Acute and Progressive
Interventions: Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibular and dynamic balance., Stretching; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 40 Years to 90 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Interventions: Not listed
Lead sponsor: LAPIX Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Baltimore, Maryland • Chevy Chase, Maryland • New York, New York + 1 more

Conditions: Multiple Sclerosis
Interventions: Natalizumab; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Relapsing Multiple Sclerosis
Interventions: Fenebrutinib, Teriflunomide, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 12
States / cities: Cullman, Alabama • Phoenix, Arizona • Torrance, California + 9 more

Conditions: Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Simvastatin; Drug
Lead sponsor: Alabama Neurology Associates, PC; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: OSF Healthcare System; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo (for Teriflunomide), Interferon-β; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Search by objective public record fields.

A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis

Rebif New Formulation (RNF) Quality of Life (QOL) Study

Vitamin D Pilot Study in Patients With Multiple Sclerosis

Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)

Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

Safety of RG2077 in Patients With Multiple Sclerosis

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

An Extension of the TG1101-RMS201 Trial

Effects of Chiropractic Care on Cytokine Levels in Multiple Sclerosis

An Examination of Cognitive Fatigue Using Functional Neuroimaging

Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis

Home Based Functional Balance Intervention for Multiple Sclerosis

An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

Short-term B-cell Depletion in Relapsing Multiple Sclerosis

A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis

Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis